Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

19. Juni 2020 11:45 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Presents Preclinical FIX Gene Therapy Data in an Oral Presentation at the World Federation of Hemophilia Virtual Summit 2020

SOUTH SAN FRANCISCO, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today presented data from preclinical studies of its hemophilia B gene therapy CB 2679d-GT...
18. Juni 2020 09:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced the pricing of an underwritten public offering of 4,615,384 shares of its...
17. Juni 2020 16:01 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) today announced that it is offering shares of its common stock in an underwritten public...
15. Juni 2020 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Appoints Clinton Musil as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced the appointment of Clinton Musil as its new chief financial officer,...
15. Juni 2020 07:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Presents Positive Final Data from its Phase 2b Trial of Subcutaneous Dalcinonacog Alfa (DalcA) at the World Federation of Hemophilia Virtual Summit 2020

SOUTH SAN FRANCISCO, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced final efficacy and safety data from its Phase 2b trial of DalcA, a...
12. Juni 2020 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Present at the Raymond James Human Health Innovation Conference

SOUTH SAN FRANCISCO, Calif., June 12, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst...
10. Juni 2020 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Completes MarzAA Pharmacokinetic & Pharmacodynamic Study

SOUTH SAN FRANCISCO, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a biopharmaceutical company developing novel subcutaneous (SQ) therapies for hemophilia and...
08. Juni 2020 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Oral and Poster Presentations at the World Federation of Hemophilia Virtual Summit 2020

SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced oral and poster presentations at the upcoming World Foundation of Hemophilia...
11. Mai 2020 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Reports First Quarter 2020 Operating & Financial Results and Provides a Corporate Update

MarzAA Phase 3 study first patient enrollment targeted before year end following FDA and EMA regulatory feedback DalcA Phase 2b study completed, final data to be presented in the second quarter ...
28. April 2020 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Receives Patent in the European Union for Its Factor IX Portfolio

SOUTH SAN FRANCISCO, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a biopharmaceutical company developing novel subcutaneous (SQ) therapies for hemophilia and...

Vorherige Seite